Literature DB >> 25960020

Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages.

M Joglekar1, S Khandelwal1, D B Cines2, M Poncz3, L Rauova3, G M Arepally1.   

Abstract

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an iatrogenic complication of heparin therapy caused by antibodies to a self-antigen, platelet factor (4) and heparin. The reasons why antibodies form to PF4/heparin, but not to PF4 bound to other cellular glycosaminoglycans are poorly understood.
OBJECTIVE: To investigate differences in cellular responses to cell-bound PF4 and PF4/heparin complexes, we studied the internalization of each by peripheral blood-derived monocytes, dendritic cells and neutrophils. METHODS AND
RESULTS: Using unlabeled and fluorescently-labeled antigen and/or labeled monoclonal antibody to PF4/heparin complexes (KKO), we show that PF4/heparin complexes are taken up by monocytes in a heparin-dependent manner and are internalized by human monocytes and dendritic cells, but not by neutrophils. Complexes of PF4/low-molecular-weight heparin and complexes composed of heparin and murine PF4, protamine or lysozyme are internalized similarly, suggesting a common endocytic pathway. Uptake of complexes is mediated by macropinocytosis, as shown by inhibition using cytochalasin D and amiloride. Internalized complexes are transported intact to late endosomes, as indicated by co-staining of vesicles with KKO and lysosomal associated membrane protein-2 (LAMP-2). Lastly, we show that cellular uptake is accompanied by expression of MHCII and CD83 co-stimulatory molecules.
CONCLUSIONS: Taken together, these studies establish a distinct role for heparin in enhancing antigen uptake and activation of the initial steps in the cellular immune response to PF4-containing complexes.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  heparin; monocytes; phagocytosis; pinocytosis; platelet factor 4

Mesh:

Substances:

Year:  2015        PMID: 25960020      PMCID: PMC4516590          DOI: 10.1111/jth.13003

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  46 in total

Review 1.  Particulate vaccines: on the quest for optimal delivery and immune response.

Authors:  Marie-Luce De Temmerman; Joanna Rejman; Jo Demeester; Darrell J Irvine; Bruno Gander; Stefaan C De Smedt
Journal:  Drug Discov Today       Date:  2011-05-04       Impact factor: 7.851

2.  Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells.

Authors:  M Svensson; B Stockinger; M J Wick
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

3.  Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.

Authors:  G M Arepally; S Kamei; K S Park; K Kamei; Z Q Li; W Liu; D L Siegel; W Kisiel; D B Cines; M Poncz
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

4.  Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?

Authors:  L Thiele; B Rothen-Rutishauser; S Jilek; H Wunderli-Allenspach; H P Merkle; E Walter
Journal:  J Control Release       Date:  2001-09-11       Impact factor: 9.776

5.  Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.

Authors:  Jurjen Tel; Annechien J A Lambeck; Luis J Cruz; Paul J Tacken; I Jolanda M de Vries; Carl G Figdor
Journal:  J Immunol       Date:  2010-03-19       Impact factor: 5.422

6.  Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis.

Authors:  Tamam Bakchoul; Heike Zöllner; Jean Amiral; Simon Panzer; Sixten Selleng; Thomas Kohlmann; Sven Brandt; Mihaela Delcea; Theodore E Warkentin; Ulrich J Sachs; Andreas Greinacher
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

7.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

8.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

9.  Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

Review 10.  Endocytosis unplugged: multiple ways to enter the cell.

Authors:  Sudha Kumari; Swetha Mg; Satyajit Mayor
Journal:  Cell Res       Date:  2010-02-02       Impact factor: 25.617

View more
  11 in total

1.  Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.

Authors:  Sufeng Zhang; Won Joon Cho; Amy T Jin; Lie Yun Kok; Yunhua Shi; David E Heller; Young-Ah Lucy Lee; Yixuan Zhou; Xi Xie; Joshua R Korzenik; Jochen K Lennerz; Giovanni Traverso
Journal:  Adv Healthc Mater       Date:  2020-06-29       Impact factor: 9.933

2.  The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21).

Authors:  Sanjay Khandelwal; Grace M Lee; C Garren Hester; Mortimer Poncz; Steven E McKenzie; Bruce S Sachais; Lubica Rauova; Garnett Kelsoe; Douglas B Cines; Michael Frank; Gowthami M Arepally
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113

3.  Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia.

Authors:  Douglas B Cines; Serge V Yarovoi; Sergei V Zaitsev; Tatiana Lebedeva; Lubica Rauova; Mortimer Poncz; Gowthami M Arepally; Sanjay Khandelwal; Victoria Stepanova; Ann H Rux; Adam Cuker; Cecilia Guo; Linnette Mae Ocariza; Richard J Travers; Stephanie A Smith; Hugh Kim; James H Morrissey; Edward M Conway
Journal:  Blood Adv       Date:  2016-11-22

4.  Interleukin 18, soluble cluster of differentiation 40, platelet factor 4 variant 1, and neutrophil gelatinase-associated lipocalin can be used as biomarkers to aid activity and diagnosis in ocular Behçet's disease.

Authors:  Fatih Celik; Ebru Coteli; Fatih Cem Gul; Ercan Ozsoy; Sabiha Gungor Kobat; Zuhal Karaca Karagoz; Suna Aydin; Kader Ugur; Meltem Yardim; İbrahim Sahin; Mehmet Hanifi Yalcin; Ramazan Fazil Akkoc; Suleyman Aydin
Journal:  Int Ophthalmol       Date:  2022-05-27       Impact factor: 2.029

Review 5.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

Review 6.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

Review 7.  Heparin: Effects upon the Glycocalyx and Endothelial Cells.

Authors:  Bruce D Spiess
Journal:  J Extra Corpor Technol       Date:  2017-09

Review 8.  Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT).

Authors:  Lubica Rauova; Gowthami Arepally; Mortimer Poncz; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2018-08-10       Impact factor: 9.754

Review 9.  Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.

Authors:  Dennis McGonagle; Gabriele De Marco; Charles Bridgewood
Journal:  J Autoimmun       Date:  2021-05-19       Impact factor: 7.094

Review 10.  Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.

Authors:  Jason B Giles; Elise C Miller; Heidi E Steiner; Jason H Karnes
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.